Extended Data Fig. 2: Activity of MRTX1133 in KRASG12D-mutant and non KRASG12D-mutant cell line models.
From: Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Evaluation of pERK modulation and cell viability in 2D and 3D assay formats in a panel of 25 KRASG12D and 11 non-KRASG12D cells. For pERK evaluation, an In-Cell Western blot assay was used to evaluate modulation of pERK in cells treated for 3 hours with MRTX1133 over a dose response. For cell viability evaluations, CellTiter-Glo assays were used to evaluate anti-proliferative activity of cells treated with a dose response of MRTX1133 and grown in 2D tissue culture conditions in a 3-day assay, or 3D conditions using 96-well, ULA plates in a 8-day assay. 3000 for 2D and 1000 for 3D indicates IC50 values were outside of the range of the assay.
